efavirenz has been researched along with Tuberculosis, Drug-Resistant in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chirehwa, MT; Court, R; De Kock, M; de Vries, N; Denti, P; Gumbo, T; Harding, J; Maartens, G; McIlleron, H; Resendiz-Galvan, JE; Warren, R; Wiesner, L | 1 |
| Budhathoki, C; Dooley, KE; Farley, JE; Geiger, K; Lowensen, K; Ndjeka, N; Ngozo, J; Patil, A | 1 |
| de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M | 1 |
1 trial(s) available for efavirenz and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Adult; Alkynes; Aminosalicylic Acid; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cross-Over Studies; Cyclopropanes; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
2 other study(ies) available for efavirenz and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
Topics: Adult; Alkynes; Antitubercular Agents; Female; Humans; Moxifloxacin; Tuberculosis, Multidrug-Resistant | 2023 |
Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity.
Topics: Adult; Antitubercular Agents; Antiviral Agents; Female; HIV Infections; Humans; Male; Protease Inhibitors; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2023 |